Skip to content
Mosunetuzumab And Same-day Pegfilgrastim w/ ddAC episode artwork

Jan 5, 2023 20 min

Mosunetuzumab And Same-day Pegfilgrastim w/ ddAC

from OncoPharm Hosted by John Bossaer

New Year - New Drug, mosunetuzumab (a CD3-CD20 T-cell engager) is approved for r/r Follicular Lymphoma. And an intriguing retrospective cohort study found a higher rate of neutropenia with same-day pegfilgrastim in patients receiving dose-dense AC. Link: https://doi.org/10.1177/10781552221148116

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Mosunetuzumab And Same-day Pegfilgrastim w/ ddAC

0:00 20:35

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OncoPharm?

This episode is 20 minutes long.

When was this OncoPharm episode published?

This episode was published on January 5, 2023.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.